At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 495 enrolled
Drug / intervention
5000 Units unfractionated Heparin Q 8 hr +1 moredrug
Likely dose
5000 Units unfractionated Heparin Q 8 hrfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
In Brief
A Phase 4 clinical trial evaluating 5000 Units unfractionated Heparin Q 8 hr and 30mg enoxaparin Q12 hr for Venous Thromboembolic Disease and 2 related conditions. Completed, enrolled 495 participants across 1 site.
Detailed Summary
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of patients given a standard every 12 hour dose of low molecular weight heparin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionSep 2014
Study CompletionOct 2014
TodayJul 2026
First PostedNov 20, 2012
Enrollment StartNov 1, 2012
Primary CompletionSep 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago
Interventions
5000 Units unfractionated Heparin Q 8 hrdrug
Venous thromboembolic prophylaxis medication
30mg enoxaparin Q12 hrdrug
Venous thromboembolic prophylaxis